No Data
No Data
Changes in Hong Kong stocks | Genting Xinyao B (01952) rose more than 6% in the afternoon, and the first prescription for the new nephropathy drug, Tolifukang, was launched in mainland China
Genting Xinyao B (01952) rose more than 6% in the afternoon. As of press release, it had risen 5.46% to HK$24.15, with a turnover of HK$74.9047 million.
[Broker Focus] BOC International's first purchase rating for 5 biotech companies indicates that it is firmly optimistic about the sector's potential for heavy snow
Jinwu Financial News | BOC International released an in-depth report on the biotechnology industry. In 2024, the State Council government work report first proposed speeding up the development of the innovative pharmaceutical industry, building new types of productivity such as biomantry, and encouraging entrepreneurship and equity investment. The bank believes that it will continue to introduce supporting policies in the future to promote the development momentum of pharmaceutical innovation. The bank believes that the sector has opportunities for valuation repair within 2024, mainly considering: 1) there has been a large degree of disconnection in the past year, and the bank is optimistic about the chances of Hong Kong stocks recovering compared to US stocks; 2) important overseas events such as overseas licensing/mergers and acquisitions transactions are expected to continue to be implemented in 2024.
The world's first IgA nephropathy treatment was successfully prescribed for resistance to the drug fukang, and the price per bottle was only one-tenth of the US
With the successful dispensing of Nifukang's first prescription, the cost of its treatment attracted widespread attention in the market.
Genting Xinyao (01952) announced that the world's first prescription for IgA nephropathy is resistant to the drug fukang in mainland China and opens a new era of IgA nephropathy treatment
Zhitong Finance App learned that Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, it was announced that Nefucan (budesonide enteric capsules, NEFECON) has successfully implemented its first prescription in China, marking that the world's first drug for IgA nephropathy has officially benefited patients in mainland China, opening a new chapter in the treatment of the causes of IgA nephropathy in China. China is one of the countries with the highest incidence of primary glomerular diseases in the world, and as a common primary glomerular disease, IgA nephropathy accounts for about 35% to 50%. studying
Genting Xinyao Announces the World's First IgA Renal Treatment Drug Endurance in Mainland China, Launching a New Era of IgA Renal Treatment
SHANGHAI, MAY 14, 20242/BEAUTY COMMUNICATION/ -- GÜNDING XINYAO (HKEX 1952.HK), A BIOPHARMACEUTICAL COMPANY FOCUSED ON INNOVATIVE DRUG AND VACCINE R&D, CLINICAL DEVELOPMENT, MANUFACTURING AND COMMERCIALIZATION, TODAY ANNOUNCED THAT NAECHANG (PUDINE NEFECON CAPSULE) HAS SUCCESSFULLY LANDED THE FIRST PRESCRIPTION IN CHINA. Encouraging the launch of the world's first IgA kidney disease treatment drug to patients in mainland China, it opens a new chapter in the treatment of IgA kidney disease in China. China is one of the countries with the highest incidence of primary kidney disease in the world, as a common primary renal cell
Genting Xinyao (01952) announced that the Macau Drug Administration of China approved the marketing license application for a new drug using itramod (VELSIPITY) for the treatment of moderate to severe active ulcerative colitis
Genting Xinyao (01952) is a biopharmaceutical company focusing on R&D, clinical development, manufacturing and commercialization of innovative drugs and vaccines. Today, the Macau Special Administrative Region Drug Administration has officially approved the marketing license application for VELSIPITY (etrasimod) for the treatment of adult patients with moderate to severe active ulcerative colitis.
No Data